Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (Entitlement Offer).

Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 million, and announced the completion of the Retail Entitlement Offer on 23 March 2022, which raised approximately $4.3 million. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.